Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acqui

Novartis has halted development of an experimental drug ​for amyotrophic lateral sclerosis after it

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper dr

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure,

Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective i

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previ

Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developi

The bad diagnoses just keep on coming for the Swiss drugmaker.

Novartis (NVS), the global innovative-medicines company, confronted sharper questions over its dealm

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sh

Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbac

HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price t

Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs,

A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve

Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, a

NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as in

Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Com

Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, whic

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses

Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne

Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) dru

Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wa

AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical

Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a

Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to me

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Predict

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac

NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III L

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s

Europe closed mixed as the AfD's Saxony-Anhalt landslide and $97 Brent lifted bond yields, and W

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascul

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effect

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutini

U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext In

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's str

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

https://www.gov.uk/government/news/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-ur

FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling el

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the co

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus